Abstract
Cancer is at present one of the utmost deadly diseases worldwide. Past efforts in cancer research have focused on natural medicinal products. Over the past decades, a great deal of initiatives was invested towards isolating and identifying new marine metabolites via pharmaceutical companies, and research institutions in general. Secondary marine metabolites are looked at as a favorable source of potentially new pharmaceutically active compounds, having a vast structural diversity and diverse biological activities; therefore, this is an astonishing source of potentially new anticancer therapy. This review contains an extensive critical discussion on the potential of marine microbial compounds and marine microalgae metabolites as anticancer drugs, highlighting their chemical structure and exploring the underlying mechanisms of action. Current limitation, challenges, and future research pathways were also presented.
| Original language | English |
|---|---|
| Article number | 476 |
| Journal | Marine Drugs |
| Volume | 18 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2020 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
-
SDG 14 Life Below Water
Keywords
- Cancer
- Clinical studies
- In vitro
- In vivo
- Marine
- Microalgae
- Microbes
- Prevention
- Therapy
Fingerprint
Dive into the research topics of 'Marine cyanobacteria and microalgae metabolites—A rich source of potential anticancer drugs'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver